Translate Bio Inc (NASDAQ:TBIO) Shares Purchased by Baupost Group LLC MA

Baupost Group LLC MA grew its stake in Translate Bio Inc (NASDAQ:TBIO) by 36.2% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 8,844,239 shares of the company’s stock after purchasing an additional 2,352,941 shares during the period. Translate Bio comprises approximately 1.0% of Baupost Group LLC MA’s investment portfolio, making the stock its 25th largest holding. Baupost Group LLC MA owned 17.34% of Translate Bio worth $109,372,000 at the end of the most recent reporting period.

A number of other institutional investors also recently added to or reduced their stakes in TBIO. Artal Group S.A. raised its stake in shares of Translate Bio by 25.0% during the 2nd quarter. Artal Group S.A. now owns 750,000 shares of the company’s stock worth $9,473,000 after buying an additional 150,000 shares during the period. Northern Trust Corp increased its stake in shares of Translate Bio by 7.5% in the 2nd quarter. Northern Trust Corp now owns 310,246 shares of the company’s stock worth $3,919,000 after acquiring an additional 21,593 shares during the last quarter. Monashee Investment Management LLC acquired a new stake in shares of Translate Bio in the 2nd quarter worth $3,789,000. Fosun International Ltd increased its stake in shares of Translate Bio by 56.1% in the 1st quarter. Fosun International Ltd now owns 115,488 shares of the company’s stock worth $1,138,000 after acquiring an additional 41,488 shares during the last quarter. Finally, Bank of New York Mellon Corp grew its holdings in shares of Translate Bio by 6.9% during the 2nd quarter. Bank of New York Mellon Corp now owns 85,689 shares of the company’s stock worth $1,083,000 after purchasing an additional 5,544 shares during the period. Institutional investors and hedge funds own 72.68% of the company’s stock.

TBIO opened at $10.06 on Friday. Translate Bio Inc has a 52 week low of $4.81 and a 52 week high of $14.34. The business’s 50 day moving average is $9.29 and its two-hundred day moving average is $9.89. The company has a quick ratio of 7.67, a current ratio of 7.67 and a debt-to-equity ratio of 1.15.

Translate Bio (NASDAQ:TBIO) last released its quarterly earnings results on Wednesday, July 31st. The company reported ($0.57) EPS for the quarter, missing the consensus estimate of ($0.48) by ($0.09). Translate Bio had a negative return on equity of 84.22% and a negative net margin of 2,696.98%. The firm had revenue of $1.17 million for the quarter, compared to analyst estimates of $1.73 million. Sell-side analysts forecast that Translate Bio Inc will post -1.96 EPS for the current year.

TBIO has been the subject of a number of research analyst reports. Roth Capital initiated coverage on Translate Bio in a report on Tuesday, June 18th. They set a “buy” rating and a $25.00 price target for the company. Zacks Investment Research upgraded Translate Bio from a “sell” rating to a “hold” rating in a report on Tuesday, July 16th. Citigroup set a $17.00 price target on Translate Bio and gave the company a “buy” rating in a research report on Tuesday, September 10th. HC Wainwright reaffirmed a “buy” rating and issued a $21.00 price target on shares of Translate Bio in a research report on Thursday, August 1st. Finally, Jefferies Financial Group began coverage on Translate Bio in a research report on Monday, July 22nd. They issued a “buy” rating and a $20.00 price target on the stock. Two investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus price target of $21.60.

About Translate Bio

Translate Bio, Inc, a clinical-stage messenger RNA (mRNA) therapeutics company, develops medicines to treat diseases caused by protein or gene dysfunction. The company is developing MRT5005, which is in Phase I/II clinical trial for the treatment of cystic fibrosis; and MRT5201 to treat ornithine transcarbamylase deficiency.

Featured Story: What is a Buy-Side Analyst?

Institutional Ownership by Quarter for Translate Bio (NASDAQ:TBIO)

Receive News & Ratings for Translate Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Translate Bio and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply